HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer by Denkert, Carsten Michael et al.
RESEARCH ARTICLE Open Access
HER2 and ESR1 mRNA expression levels and
response to neoadjuvant trastuzumab plus
chemotherapy in patients with primary breast
cancer
Carsten Denkert
1*†, Jens Huober
2,3†, Sibylle Loibl
4, Judith Prinzler
1, Ralf Kronenwett
5,6,7, Silvia Darb-Esfahani
1,
Jan C Brase
6, Christine Solbach
8, Keyur Mehta
4, Peter A Fasching
9, Bruno V Sinn
1, Knut Engels
10, Mattea Reinisch
4,
Martin-Leo Hansmann
10, Hans Tesch
11, Gunter von Minckwitz
4 and Michael Untch
12
Abstract
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to
expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core
biopsies of HER2-positive breast carcinomas from patients treated within the neoadjuvant GeparQuattro trial.
Methods: HER2 levels were centrally analyzed by immunohistochemistry (IHC), silver in situ hybridization (SISH) and
qRT-PCR in 217 pretherapeutic formalin-fixed, paraffin-embedded (FFPE) core biopsies. All tumors had been HER2-
positive by local pathology and had been treated with neoadjuvant trastuzumab/ chemotherapy in GeparQuattro.
Results: Only 73% of the tumors (158 of 217) were centrally HER2-positive (cHER2-positive) by IHC/SISH, with
cHER2-positive tumors showing a significantly higher pCR rate (46.8% vs. 20.3%, P <0.0005). HER2 status by qRT-PCR
showed a concordance of 88.5% with the central IHC/SISH status, with a low pCR rate in those tumors that were
HER2-negative by mRNA analysis (21.1% vs. 49.6%, P <0.0005). The level of HER2 mRNA expression was linked to
response rate in ESR1-positive tumors, but not in ESR1-negative tumors. HER2 mRNA expression was significantly
associated with pCR in the HER2-positive/ESR1-positive tumors (P = 0.004), but not in HER2-positive/ESR1-negative
tumors.
Conclusions: Only patients with cHER2-positive tumors - irrespective of the method used - have an increased pCR
rate with trastuzumab plus chemotherapy. In patients with cHER2-negative tumors the pCR rate is comparable to
the pCR rate in the non-trastuzumab treated HER-negative population. Response to trastuzumab is correlated to
HER2 mRNA levels only in ESR1-positive tumors. This study adds further evidence to the different biology of both
subsets within the HER2-positive group.
Introduction The human epidermal growth factor receptor 2 (HER2) is the prototype of a predictive biomarker for
targeted treatment [1-8]. International initiatives have established the combination of immunohistochemistry (IHC)
and in situ hybridization as the current gold standard [9,10]. As an additional approach determination of HER2
mRNA expression is technically feasible in formalin-fixed paraffin-embedded (FFPE) tissue [11-13]. Crosstalk between
the estrogen receptor (ER) and the HER2 pathway has been suggested based on cell culture and animal models
[14]. Consequently, the 2011 St Gallen panel has pointed out that HER2-positive tumors should be divided into two
groups based on expression of the ER [15].
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any medium, provided the original work is properly cited.A retrospective analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 study has
suggested that mRNA levels of HER2 and ESR1 might be relevant for the degree of benefit from adjuvant
trastuzumab. By subpopulation treatment effect pattern plot (STEPP) analysis in ER-positive tumors, benefit from
trastuzumab was shown to be restricted to those with higher levels of HER2 mRNA (S Paik, personal
communication, results summarized in [15]).
In our study we evaluated this hypothesis in the neoadjuvant setting in a cohort of 217 patients from the
neoadjuvant GeparQuattro trial [5]. All patients had been HER2- positive by local pathology assessment and had
received 24 to 36 weeks of neoadjuvant trastuzumab plus an anthracycline/taxane-based chemotherapy. For
central evaluation we used three different methods, HER2 IHC, and HER2 silver in situ hybridization (SISH), as well
as measurement of HER2 mRNA by quantitative real-time (qRT)-PCR [11].
The primary objective of this analysis was to investigate if pathological complete response (pCR) rate in HER2-
positive breast cancer would depend on the level of HER2 mRNA expression, with a separate analysis for HR-
positive and -negative tumors. Central evaluation of the HER2 status showed that 27% of the tumors with HER2
overexpression by local pathology were HER2-negative. This enabled us to compare response rates in patients with
HER2-positive and -negative tumors as a secondary objective.
Materials and methods
Study population
The multicenter neoadjuvant phase III GeparQuattro
trial (NCT 00288002) recruited a total of 1,509 patients
between August 2005 and November 2006. Treatment
was four cycles of epirubicin/cyclophosphamide followed
by four cycles of docetaxel with or without capecitabine
[16]. Patients with HER2-positive tumors (n = 445, based
on local assessment) received trastuzumab/chemotherapy
[5]. FFPE pretherapeutic core biopsies were collected,
after written informed consent as part of the prospec-
tively planned collection of biomaterials. Ethical commit-
tee approval was obtained for all centers participating in
the clinical studies and from the institutional review
board of the Charité hospital. A complete pathological
response was defined as the pathologically confirmed
absence of residual invasive tumor in breast and lymph
nodes at surgery. This definition was prospectively
defined for this biomarker study before the start of the
statistical evaluation in concordance with previous
studies [12,17].
Inclusion criteria for the use of biomaterials were the
availability of tissue samples from pretherapeutic core
biopsies with at least 30% tumor tissue and successful
RNA isolation. IHC (rabbit polyclonal anti-HER2
antibody, Clone A0485, DakoCytomation, Hamburg,
Germany) and SISH (Inform-SISH system, Ventana,
Tucson, AZ, USA) were stained on the Ventana Discovery
Autostainer. IHC was performed on 217 cases using large
sections, while SISH was performed on a tissue-microarray
(TMA) for those 156 cases with available tissue on the
TMA. A centrally confirmed HER2-positive status was
defined as either IHC 3+ or IHC 2+/SISH ratio >2.0
[9,10]. The study was reported in concordance with the
reporting recommendations for tumor marker prognostic
studies (REMARK) criteria [18,19].
Sample preparation and RNA extraction
RNA was isolated from 10-µm FFPE sections using the
VERSANT Tissue Preparation System (Siemens Health-
care Diagnostics, Tarrytown, NY, USA) as described
earlier [20-22]. Samples had sufficient RNA if the mean
of cycle threshold (Ct) values of three reference genes
CALM2, OAZ1 and RPL37A was below 30.6. DNA con-
tamination was assessed by HBB gene-specific qPCR; Ct
values above 36 were required.
Gene expression analysis using quantitative RT-PCR
Primer and probe sequences have been described else-
where [23]. qRT-PCR was performed in triplicate using
the SuperScript III PLATINUM One-Step qRT-PCR
System with ROX (Invitrogen, Karlsruhe, Germany) in
an Agilent Mx3005 (Agilent, Böblingen, Germany) with
30 minutes at 50°C, 2 minutes at 95°C followed by 40
cycles of 15 sec at 95°C and 30 sec at 60°C. Relative
expression levels of genes of interest (GOI) were calcu-
lated as ΔCt values as follows:
Ct = 20 −

CtGOI − Ct( m e a no fR P L 3 7 A ,C A L M 2 ,O A Z 1 )

.
No-template controls as well as a standardized refer-
ence RNA (Stratagene qPCR Human Reference Total
RNA, Agilent Technologies, Waldbronn, Germany) were
used as controls.
ESR1 and HER2 cutoff values were predefined based
on previous studies [11,20,24]. Since different platforms,
normalization strategies and primer/probe lots had been
used a constant target-specific shift in Ct values between
previous and current assay conditions occurred. The
cutoffs from the published previous studies were there-
fore transformed by addition of an offset. The offsets for
ESR1 and HER2 were predetermined for this study by
reassessment of the 167 samples from the previous
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cutoffs of 19.5 for HER2 mRNA and 13.8 for ESR1
mRNA. These cutoffs are therefore numerically differ-
ent, but identical with regard to mRNA levels to the
previously published cutoffs. Trained laboratory person-
nel performed all PCR assays with predefined protocols.
All analyses (including the central pathology review)
were performed blinded to the clinical data.
Statistical evaluation
Statistical analysis was performed using SPSS version
19.0 (IBM, Armonk, NY, USA). The probability of pCR
as a function of gene expression parameters was deter-
mined by univariate logistic regression analysis. The two-
sided Fisher´s exact test was used for comparison of pCR
rates. STEPP analysis was performed as suggested [25,26]
using a sliding window approach of 40 samples with an
overlap between windows of 10 cases. pCR rates and
mean HER2 mRNA levels were calculated separately for
each window for all cases, as well as the two subgroups
based on ESR1 mRNA expression.
Results
Baseline clinical data, consort statement and central
evaluation of HER2
The consort statement and clinical characteristics are
shown in Figure 1 and Table 1. A total of 261 samples
were prospectively collected, of which 33 contained less
than 30% tumor tissue. RNA isolation was possible in
217 cases (95.1% of 228). For 158 tumors (72.8% of 217)
the local HER2-positive status was confirmed. The
remaining 59 tumors (27.2%) were centrally HER2-nega-
tive (cHER2-negative status) despite a locally positive
HER2 status. Interestingly, the discordance rate was sig-
nificantly higher in ESR1-positive tumors (34.5%) than
in ESR1-negative tumors (18.4%, P =0 . 0 0 9 ,t w o - s i d e d
Fisher´s test).
Concordance of different methods for determination of
HER2 to predict response to neoadjuvant trastuzumab/
chemotherapy
Additional analyses were performed to validate cHER2
assessment. In addition to the current definition of a
positive HER2 status (IHC3+ or IHC2+/SISH >2.0), we
used HER2 IHC alone, HER2 SISH ratio, and HER2
SISH copy number, as well as HER2 qRT-PCR. For
HER2 mRNA the positive concordance with the current
diagnostic standard was 86.7%, the negative concordance
was 93.2% and the total concordance was 88.5% (192 of
217 cases, Table 1).
As shown in Figure 2A, the pCR rate was significantly
higher in the cHER2-positive cases. cHER2-positive
cases, defined by either IHC/SISH combined, IHC alone,
SISH copy number or SISH ratio, had pCR rates of 47%,
47%, 54% and 53%, while the cHER2-negative cases had
pCR rates of only 20 to 23% (P = 0.004, for IHC alone,
P <0.0005 for all other comparisons, two-sided Fisher’s
test) (Figure 2). For HER2 mRNA the pCR rate was
49.6% for the mRNA-positive group and 21.1% for the
mRNA-negative group (P <0.0005, two-sided Fisher´s
test) (Figure 2).
High concordance of 89.2% between HER2 mRNA
levels and the SISH ratio was observed (Figure 2B,
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Figure 1 Consort statement indicating the flow of samples
through the study. HER2, human epidermal growth factor receptor
2; FFPE, formalin-fixed paraffin-embedded; Ct, cycle threshold; ESR1,
estrogen receptor 1; RT-PCR, real-time polymerase chain reaction.
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Page 3 of 12Table 1 Clinico-pathological data of the study cohort
Characteristic All cases, number (%) Centrally evaluated HER2-
positive cases, number (%)
Centrally evaluated HER2-
negative cases, number (%)
Samples, number 217 158 59
Local HER2 status (IH/ISH)
positive 217 (100) 158 (100) 59 (100)
negative 0 (0) 0 (0) 0 (0)
Central HER2 status (IH/SISH)
Positive 158 (72.8) 158 (100) 0 (0)
Negative 59 (27.2) 0 (0) 59 (100)
HER2 protein expression (central IH)
3+ 144 (66.4) 144 (91.1) 0 (0)
2+ 20 (9.2) 8 (5.1) 12 (20.3)
0/1+ 48 (22.1) 2 (1.3) 46 (78.0)
missing 5 (2.3) 4 (2.5) 1 (1.7)
HER2 gene amplification (central SISH)
SISH positive (>2.2) 109 (50.2) 109 (69.0) 0 (0)
SISH negative (<1.8) 49 (22.6) 10 (6.3) 39 (66.1)
SISH equivocal (1.8-2.2) 8 (3.7) 6 (3.8) 2 (3.4)
missing 51 (23.5) 33 (20.9) 18 (30.5)
HER2 mRNA expression (central qPCR)
Positive (>19.5) 141 (65.0) 137 (86.7) 4 (6.8)
Negative (≤19.5) 76 (35.0) 21 (13.3) 55 (93.2)
ER/PR Status (local IH)
ER+ and/or PR+ 125 (57.6) 84 (53.2) 41 (69.5)
ER-/PR- 92 (42.4) 74 (46.8) 18 (30.5)
ESR1 mRNA expression (central qPCR)
Positive (>13.8) 109 (50.2) 70 (44.3) 39 (66.1)
Negative (≤13.8) 108 (49.8) 88 (55.7) 20 (33.9)
Tumor grade
G1 to G2 114 (55.1) 78 (49.4) 36 (61.0)
G3 93 (44.9) 72 (45.6) 21 (35.6)
Missing 10 (4.6) 8 (5.1) 2 (3.4)
Clinical tumor stage
cT1 to cT2 155 (71.4) 110 (69.6) 45 (76.3)
cT3 to cT4 62 (28.6) 48 (30.4) 14 (23.7)
Clinical nodal status
cN0 83 (38.2) 61 (38.6) 22 (37.3)
cN+ 134 (61.8) 97 (61.4) 37 (62.7)
Pathological response
No pCR 131 (60.4) 84 (53.2) 47 (79.7)
pCR (ypT0/is ypN0) 86 (39.6) 74 (46.8) 12 (20.3)
Age group
≤ 50 years 109 (50.2) 84 (53.2) 25 (42.4)
> 50 years 108 (49.8) 74 (46.8) 34 (57.6)
Tumor type
Ductal/other 207 (95.4) 156 (98.7) 51 (86.4)
Lobular 10 (4.6) 2 (1.3) 8 (13.6)
HER2, human epidermal growth factor receptor 2; SISH, silver in situ hybridization; IH: immunohistochemistry; ISH: in situ hybridization; qPCR, quantitative
polymerase chain reaction; ypT: tumor stage after neoadjuvant therapy; ypN: nodal status after neoadjuvant therapy.
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Figure 2 Comparison of different methods for central assessment of human epidermal growth factor receptor 2 (HER2)
overexpression.( A) Five different approaches were used: IHC 3+ or IHC2+/SISH >2.0 (gold standard), HER2 IHC, HER2 SISH ratio, HER2 SISH
copy numbers as well as quantitative RT-PCR for evaluation of HER2 mRNA levels. In all approaches the pCR rate was significantly higher in the
centrally HER2-positive cases. (P = 0.004, for IHC alone, P <0.0005 for all other comparisons, two-sided Fisher’s exact test). (B) Comparison of
quantitative HER2 mRNA levels and SISH ratio; pCR cases are marked as dark spots. A total of 11 cases were negative for HER2 mRNA despite an
amplification of HER2 by SISH (lower right corner). These cases showed a pCR rate of only 27.3% (three pCRs out of eleven cases). IHC,
immunohistochemistry; SISH, silver in situ hybridization; RT-PCR, real-time polymerase chain reaction; pCR, pathological complete response, ypT:
tumor stage after neoadjuvant therapy.
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Page 5 of 12positive concordance: 90.4%, negative concordance:
86.5%). Those patients who were HER2-negative by both
methods had a pCR rate of only 20%. A total of 11 cases
were negative for HER2 mRNA despite positive SISH
(lower right corner in Figure 2B). Five of those eleven
tumors were HER2 IHC 2+ and six were HER2 IHC 3+.
These cases showed a comparably low pCR rate of only
2 7 . 3 %( t h r e ep C R si ne l e v e nc a s es). Interestingly, those
seven tumors that were mRNA-positive but SISH-negative
had a pCR rate of 43%. Four of those seven tumors were
HER2 3+ by IHC, while two were HER2 2+ and one was
HER2 0 to 1+.
For comparison of HER2 mRNA levels and SISH copy
number, concordance of 91.1% was achieved. For hor-
mone receptor (HR) status, 185 of the 217 cases were
concordant regarding the comparison of ER IHC and
ESR1 mRNAs, resulting in a concordance of 85.2%.
Quantitative assessment of ESR1 and HER2 mRNA levels
The combined quantitative determination of HER2 and
ESR1 mRNA with predefined cutoffs resulted in four
separate groups (Figure 3). If the analysis was restricted
to the 158 cHER2-positive cases (Figure 3B), a total of
21 cases (13.3%) were HER2-negative by mRNA analysis.
T h ep C Rr a t eo ft h e s e2 1c a s e sw a s2 3 . 8 %( F i g u r e3 B ) .
In contrast, the pCR rate was significantly higher in
those 137 patients who were cHER2-positive and HER2
mRNA-positive (pCR rate 50.4%, P = 0.03, two-sided
Fisher’s test).
Separate evaluation of ESR1-positive and -negative
tumors by STEPP analysis and logistic regression
The distribution of HER2 mRNA expression is different
in ESR1-positive and ESR1-negative cases. For ESR1-
negative cases HER2 mRNA has a typical bimodal distri-
bution (Figure 3E). In contrast, for ESR1-positive tumors
HER2 mRNA levels are more continuously distributed
indicating a continuum of HER2 expression in this
group (Figure 3D). This type of different distribution
was not observed for the HER2 SISH ratio.
To evaluate the impact of different levels of HER2
mRNA on pCR in the groups of ESR1-positive and
-negative tumors, we performed STEPP analysis.
As shown in Figure 3G, HER2 mRNA levels were signifi-
cantly linked to pCR rate in the group of ESR1 mRNA-
positive tumors: in this group, the pCR rate continuously
rose with increased HER2 mRNA levels. In contrast, for
ESR1 mRNA-negative tumors an abrupt increase of the
pCR rate occurred once the cutoff between HER2-
positive and -negative tumors was crossed, while HER2
mRNA levels did not further influence the pCR
rate once a tumor was in the HER2-positive group
(Figure 3H). A similar assessment using the traditional
factors, HR status by IHC and SISH copy number, did
not show a rise of pCR rates with increased SISH ratios
in HR-positive tumors (Figure 4).
In a parallel approach, odds ratios for pCR for the three
quantitative markers, ESR1 mRNA, HER2 mRNA and
SISH ratio, were determined in different subgroups. The
predictive effect of HER2 mRNA levels was particularly
strong in the group of cHER2-positive/ESR1-positive
tumors; in this group ESR1 mRNA level was also signifi-
cant (Figure 5). In contrast, HER2 as well as ESR1 mRNA
levels were not significant in cHER2-positive/ESR1-nega-
tive tumors, similar to the results of the STEPP analysis.
If the analysis was restricted to cHER2-positive cases,
ESR1 mRNA was a significant predictive marker only in
the groups of ESR1-positive tumors. Neither SISH ratio
(Figure 5) nor SISH copy number (Figure 5), was signifi-
cant in the group of cHER2-positive cases.
Discussion
Our investigation shows that in HR-positive tumors the
response to neoadjuvant treatment with trastuzumab
plus anthracyline-taxane chemotherapy is driven by the
degree of HER2 mRNA expression. This phenomenon
could not be observed in the HR-negative subset. Inter-
estingly, Soon Paik’s group has described a similar find-
ing in the adjuvant setting. While their full paper is not
published yet, a summary of their results has been
included in the recent St Gallen recommendations as
follows: ‘An interesting STEPP analysis from the adju-
vant trastuzumab NSABP B-31 trial examined the
degree of HER2 mRNA expression and corresponding
trastuzumab benefit separately for patients with estrogen
receptor-positive and estrogen receptor-negative disease.
The striking finding was that among patients with estro-
gen receptor-positive disease, trastuzumab benefit in
terms of 8-year disease-free survival was entirely con-
fined to those with the higher levels of HER2 mRNA
expression’ [15].
Similar to these findings in the adjuvant setting, there is
ac o n s i d e r a b l ed i f f e r e n c ei no u rn e o a d j u v a n ts t u d y
between ESR1-positive/HER2-positive and ESR1-negative/
HER2-positive tumors. For ESR1-negative/HER2-positive
tumors the amount of HER2 mRNA is not further relevant
for response once a tumor is in the HER2-positive group.
mRNA levels of HER2 have a dichotomous distribution
and HER2 can be used as a categorical parameter in this
group.
For ESR1-positive/HER2-positive tumors the situation
is different; HER2 mRNA has a more continuous distri-
bution and the response to neoadjuvant trastuzumab/
chemotherapy rises continuously with the amount of
HER2 mRNA within the HER2-positive tumor group.
This suggests that those luminal tumors with higher
activity of the HER2 pathway (measured as increased
mRNA levels) are more dependent on this pathway and
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Figure 3 mRNA-based combined quantitative determination of human epidermal growth factor receptor 2 (HER2) and estrogen
receptor 1 (ESR1) mRNA. Cases with a pCR are marked as dark spots. (A) Total of 217 cases. (B) Centrally HER2-positive cases (n = 158). In this
group a total of 21 cases (13.3%) were HER2-negative by mRNA analysis; the pCR rate of those 21 cases was only 23.8%. The pCR rate in those
137 cases that were HER2-positive by mRNA analysis was 50.4%, (P = 0.03, two-sided Fisher’s exact test). (C, D, E) All 217 cases: different
distribution patterns of HER2 mRNA with a continuous distribution in ESR1-positive tumors (D) and a more dichotomous distribution in ESR1-
negative tumors (E). STEPP analysis for all 217 tumors (F), ESR1-positive tumors (G) and ESR1-negative tumors (H). HER2 mRNA levels were linked
to pCR rate in the group of ESR1-positive tumors with a continuously increased pCR rate. pCR, pathological complete response; STEPP,
subpopulation treatment effect pattern plot.
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This finding is supported by the STEPP analysis and we
observed the same effect with the classical approach of
logistic regression, which also showed a significant effect
of HER2 mRNA levels (measured as a continuous vari-
able) on pCR only in the ESR1-positive/HER2-positive
group. The traditional method of HER2 SISH ratio or
copy number was not able to provide a similar result by
STEPP or logistic regression analysis, similar to the find-
ing in the adjuvant HERA trial [27].
The relevance of crosstalk between the ER pathway
and the HER2 pathway has been described in several in
vitro cell culture and animal models [14,28,29], Ampli-
fied in breast (AIB)-1 [30,31] as well as Paired box gene
2 (PAX2) [32] have been identified as relevant mediators
of this crosstalk.
The hypothesis derived from those investigations and
our results would be that two important growth factor
pathways significantly influence ESR1-positive/HER2-
positive tumors and either HER2 or ER may be the
driver of cell proliferation and survival. With sustained
HER2 inhibition ER could function as a key escape or
survival pathway, which may result in resistance to tras-
tuzumab. However when HER2 mRNA expression is
very high the primary driver of proliferation may still be
the HER2 pathway even in the presence of the activated
ER pathway. These findings are consistent with two
neoadjuvant trials where significantly lower pCR rates
were observed in ER-positive/HER-positive tumors com-
pared to ER-negative/HER2-positive disease [7,8]. How-
ever, in a recently reported neoadjuvant trial, response
rates to anti-HER2 treatment with lapatinib and trastu-
zumab (without chemotherapy) were fairly high (pCR
21%) when combined with endocrine treatment if HRs
were present [33]. As in the adjuvant setting trastuzu-
mab or lapatinib therapy (in contrast to the neoadjuvant
approach) is usually combined with endocrine therapy
in the HR-positive group; the combined inhibition of
both pathways is already used in clinical practice
[34,35]. It would be interesting to further evaluate the
contribution of the endocrine therapy to outcome in
ESR1-positive/HER2-positive tumors.
Another finding of our study is the rather high rate of
discordance of 27% between central and local evaluation
of HER2. We have validated this finding by the use of
different methods for central pathology. A similar rate
of 20% inaccurate HER2 measurements has been
reported before [9] based on results of the NSABP [36]
and the N9831 study [37,38]. Discordance has also been
observed between different reference laboratories, in
particular for borderline cases [39]. Interestingly, in our
study the discordance was higher in ESR1-positive
tumors, which might be partially due to the more con-
tinuous distribution of HER2 mRNA in this group.
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Figure 4 Subpopulation treatment effect pattern plot (STEPP) analysis using the classical parameters human epidermal growth factor
receptor 2 (HER2) silver in situ hybridization (SISH) copy number and hormone receptor immunohistochemistry. Shown are analysis for
all tumors (A), hormone receptor-positive tumors (B) and hormone receptor negative tumors (C). In contrast to the data shown ins the classical
parameters were not linked to pCR rate. pCR, pathological complete response; IHC, immunohistochemistry; HR, hormone receptor.
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Page 8 of 12Pinhel et al. [40] have also observed this different distri-
bution of HER2 mRNA in ER-positive vs -negative
tumors in a recent report.
The high level of false-positive cases gave us the possi-
bility to evaluate the response to trastuzumab in HER2-
negative tumors. Centrally HER2-negative tumors had a
p C Rr a t eo fo n l y2 0 % ,w h i c hi si nt h er a n g eo ft h ep C R
rate of HER2-negative tumors in the GeparTrio trial
(17.6%). This validates previous findings that HER2 is
the crucial biomarker for trastuzumab-based therapy.
However, it differs from an analysis of the NSABP-B31
suggesting a benefit of adjuvant trastuzumab even in
cHER2-negative tumors [41]. There are two main differ-
ences between NSABP-B31 and our study: we used the
neoadjuvant setting, which allowed us to directly study
response in the primary tumor, but we could not evalu-
ate the effects on micro-metastases as well as the contri-
bution of adjuvant endocrine therapy. Furthermore, the
rate of cHER2-negative cases in NSABP-B31 was only
9.7%, compared to 27% in our study. It would be very
interesting to await the results of the NSABP B47 [42],
which is currently evaluating the benefit of trastuzumab
in low HER2-expressing tumors.
As an additional method we have evaluated HER2
mRNA expression by qRT-PCR. Recently, Dabbs et al.
found that HER2 mRNA levels were negative by recur-
rence score in 10 (42%) of 24 HER2-positive cases [43].
The same finding had already been shown in 638 sam-
ples from the NSABP-B31 with an overlap of HER2
mRNA expression levels between HER2-positive and
Ϭ͘ϬϬ ϭ͘ϬϬ Ϯ͘ϬϬ ϯ͘ϬϬ ϰ͘ϬϬ
ĂůůĐĂƐĞƐ ESR1 mRNA 0.82 (0.74-0.91) фϬ͘ϬϬϬϱ
HER2 mRNA 1.33 (1.14-1.55) фϬ͘ϬϬϬϱ
HER2 SISH ratio 1.08 (0.96-1.22) ŶƐ
HER2 copy number 1.005 (1.002-1.008) Ϭ͘ϬϬϰ
Đ,ZϮн ESR1 mRNA 0.91 (0.80-1.03) ŶƐ
HER2 mRNA 1.34 (1.04-1.72) Ϭ͘ϬϮ
HER2 SISH ratio 0.94 (0.81-1.09) ŶƐ
HER2 copy number 1.002 (1.00-1.006) ŶƐ
Đ,ZϮн^Zϭн ESR1 mRNA 0.52 (0.34-0.79) Ϭ͘ϬϮ
HER2 mRNA 2.01 (1.24-3.25) Ϭ͘ϬϬϰ
HER2 SISH ratio 0.93 (0.75-1.14) ŶƐ
HER2 copy number 1.004 (1.00-1.01) ŶƐ
Đ,ZϮн^ZϭͲ ESR1 mRNA  0.93 (0.64-1.35) ŶƐ
HER2 mRNA 1.09 (0.81-1.48) ŶƐ
HER2 SISH ratio 0.94 (0.76-1.17) ŶƐ
HER2 copy number 1.00 (0.99-1.005) ŶƐ
Figure 5 Odds ratios for pathological complete response (pCR) for the quantitative markers estrogen receptor 1 (ESR1) mRNA (per
dCT), human epidermal growth factor receptor 2 (HER2) mRNA (per dCT), silver in situ hybridization (SISH) ratio and SISH copy
number in different subgroups. Results in the three columns (right) represent as odds ratios, 95% CI and P-values. ESR1 mRNA was significant
only in the group of all 217 cases (which also contained the centrally evaluated HER2 (cHER2)-negative cases). If the analysis was restricted to
the centrally evaluated HER2-positive cases, ESR1 mRNA was not significant. HER2 mRNA levels were only significant in the group of ESR1-
positive tumors, similar to the subpopulation treatment effect pattern plot (STEPP) analysis. In contrast to the mRNA analysis, HER2 SISH ratio and
copy number were not significant in centrally evaluated HER2-positive cases. ns, not signficant.
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Page 9 of 12-negative tumors [40]. In our study 11 cases were nega-
tive for HER2 mRNA despite positivity by SISH, and
those cases had a low pCR rate of only 27%. Further-
more seven tumors were mRNA-positive but SISH-
negative with a pCR rate of 43%. Therefore, in our small
cohort there is no evidence that patients with central
IHC-positive results but negative HER2 mRNA have
relevant benefit from trastuzumab with regard to pCR,
which raises the hypothesis that HER2 mRNA might be
more suitable for response prediction than SISH. We
would like to emphasize that the low number of cases
makes it impossible to fully evaluate this hypothesis in
the context of our study, and that currently all indica-
tions for HER2-targeted therapies should be based on
the established Food and Drug Administration (FDA)
criteria.
The differences between HER2 mRNA and the classi-
cal methods of IHC and SISH might explain the finding
that a different magnitude of benefit according to ER
status has not been seen for trastuzumab in any of the
adjuvant trastuzumab trials.
There are several limitations of our study; it was retro-
spective, the analysis could only be performed in a sub-
population, and we used only one pCR definition
without separating the group of residual ductal carci-
noma in-situ (DCIS). This separation was not possible
in our cohort due to the smaller sample size. It should
also be noted that some studies suggest that pCR might
n o tb ear e l i a b l es u r r o g a t ef o rl o n g - t e r md i s e a s eo u t -
come in ER+/HER2+ disease [44]. The advantages of
the study are that we used a population from a prospec-
tive clinical trial with a standardized assay system, as
well as a predefined hypothesis and analysis plan.
Conclusions
In summary, our results provide further evidence for
the concept that HER2-positive/non-luminal and ESR1-
positive/HERpositive tumors are different biological enti-
ties. Several randomized trials have shown that the bene-
fit of adjuvant trastuzumab is significant in the cohort of
H E R 2 - p o s i t i v et u m o r sa sw e l la si ns u b g r o u p sb a s e do n
HR expression. It would be very interesting to evaluate
HER2 mRNA levels in this context, since HER2 mRNA
expression may select those ER-positive/HER2-positive
tumors with an optimal benefit from trastuzumab.
Another important issue would be to evaluate HER2
mRNA levels for response to different types of HER2 tar-
geted agents, for example, lapatinib [45,46] or pertuzu-
mab [47]. Interestingly, a recent analysis in the NSABP
B-41 trials has suggested differences between lapatinib,
trastuzumab and their combination depending on the
protein expression level of HER2 [48]. Additional evalua-
tions are planned in the GeparQuinto and the GeparSixto
trials of the AGO B and the German Breast Group within
the European FP7 project, RESPONSIFY.
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